MiNK Therapeutics, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $52.6M
- Price
- $10.55
- % Change (Daily % change from the live per-ticker quote feed.)
- -1.13%
- Volume
- 12.3K
Quote data as of 6:13 AM ET
About
MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.
Quick stats
Shares outstanding5.0M
Computed float2.0M
Float sourceUnknown
Cash runway (months)Unknown
Dilution risk—
Has warrants—
Has convertibles—
Active shelf (Shelf registration (e.g. Form S-3) currently in effect — the company is pre-cleared to issue and sell new shares quickly. A standing dilution risk.)—
Active ATM (At-the-market offering — a program to sell newly issued shares directly into the open market at prevailing prices, diluting existing holders over time.)—
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001840229
Websitehttps://minktherapeutics.com
AI Summary
AI-generated1mo agostandardbullishclinical trialMiNK Therapeutics Announces First Patient Dosed in Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury and Critical Illness
MiNK Therapeutics has dosed the first patient in its randomized Phase 2 trial of agenT-797 for acute lung injury and critical illness.
The trial is being conducted at First Lviv Territorial Medical Union in Ukraine, marking a rapid transition from activation to treatment in a high-acuity ICU environment.
Preliminary data from the study, which evaluates survival and ventilator-free days, are expected in the second half of 2026.
Red flags
- Trial initiated in a conflict zone (Ukraine), which may pose logistical or safety risks to study continuity
- No approved therapies exist for this indication, implying high regulatory bar for efficacy